Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Medivir to present at the Redeye Life Science Day

Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Life Science Day, tomorrow November 23, 2023. CEO Jens Lindberg will participate in an In Focus interview at 13.20 CET, led by Redeye analyst Richard Ramanius, with focus on the latest developments and the company's future plans. This will include, among other things, the company's proposed rights issue and how it aims to ensure the highest possible speed and

STILFOLD introduces AI to empower “industrial origami” design and manufacturing technology

STILFOLD - the Swedish startup renowned for its origami-inspired approach to design and manufacturing - is joining forces with Linköping University to optimise the performance of its sustainable manufacturing technology using artificial intelligence.The STILFOLD  technology, dubbed “industrial origami”, involves the use of robotic arms to fold flat sheet metal over curves to form light and sustainable new structures using minimal component parts. The technology is currently being used to build the chassis of a light electric motorcycle called the STILRIDE 1 

Svenska Aerogel receives another order for 2.2 tons – customer orders 44% more material this year compared to last year

A returning European customer has placed yet another order for 2.2 tons of Quartzene[®], marking a repetition of its largest order. With this new order, it becomes clear that the customer has ordered 44% more of Svenska Aerogel’s material in 2023 compared to 2022. The customer operates in Building & Construction, an industry that has faced a challenging year. However, the order indicates an improvement for the customer, whose product is excellent for energy renovations in buildings.[En bild som visar inomhus, Paketeringsmaterial, lager, kartong Automatiskt genererad beskrivning]

BioStock: Stayble Therapeutics shifts focus to phase Ib study in disc herniation

Following dissapointing results from the phase IIb study, Stayble Therapeutics is shifting its focus to the phase Ib study in hearniated disc patients. At the same time, the company plans to reduce costs in order to complete the study without additional funding. CEO Andreas Gerward shares more details in an interview with BioStock.Read the full article at biostock.se: https://www.biostock.se/en/2023/11/stayble-therapeutics-shifts-focus-to-phase-ib-study-in-disc-herniation/ This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se

Image System's business area RemaSawco receives an order from Moelven Dalaträ for just over SEK 4.6 million

RemaSawco AB has signed an agreement with Moelven Dalaträ AB to upgrade the sawmill's saw line intake, saw line and green sorting where the total value amounts to just over SEK 4.6 million.The agreement involves a modernization of the sawmill in Mockfjärd where the sawline intake gets a new control and measurement system and both the sawline and green sorting get several upgrades. The agreement also includes commissioning and training of the customer's staff. Delivery, installation and commissioning will take place during the summer of 2024. "We are grateful for our very good

First day to exercise Catena Media’s warrants (CTM TO1) for subscription of new shares during 15th exercise period

Catena Media plc today announces that the 15th period to subscribe for shares in the company by exercise of warrants (ticker CTM TO1) (“the warrants”) commences today, 22 November 2023, and will run until and including 1 December 2023. During this period, each warrant entitles the holder to subscribe for one (1) new share in the company at a subscription price of SEK 18.90. Payment of subscribed shares can be made in cash or through set-off with the full nominal amount of each hybrid capital security (ticker CATME HO1) that the warrant holder uses for set-off. The nominal amount of one (

Q3 Report – 30 September 2023

Flexion reports positive momentum towards the end of Q3 and includes strong earnings estimates for October.July-September 2023 performance · Total revenue decreased by 20% to GBP 14.8m (18.5)* · Gross profit decreased by 16% to GBP 2.5m (3.0) · Adjusted EBITDA[‡] decreased by 55% to GBP 0.7m (1.5) · Operating result decreased to GBP -0.4m (-0.3m) · EPS amounted to GBP -1.24 pence (-1.25 pence) · Operating cash flow amounted to GBP -2.0m (2.0) · Cash and cash equivalents decreased to GBP 7.5m (10.5) January-September 2023 performance · Total revenue decreased

Thailand travel insight tips from our guru

Thailand is renowned for its vibrant culture, stunning landscapes, and warm hospitality. It has been a magnet for travelers who seek adventure and want to connect with true local culture. With its diverse offerings, from bustling cities like Bangkok to serene beaches in Krabi and lush rainforests in Chiang Mai, Thailand caters to a wide range of interests for every lifestyle.   To help you explore Thailand like a local, we've compiled a list of Thailand's experts, individuals who possess an insight knowledge of the country's hidden gems and off-the-beaten-path experiences

Implantica publishes Interim Report January – September 2023 (Q3)

RefluxStop™ – Beginning of a New Era of Acid Reflux TreatmentSignificant events in the third quarter of 2023 · A big milestone was achieved in the U.K. with our first NHS RefluxStop™ implants performed at St. Mary’s Hospital, London, part of the Imperial Healthcare NHS Trust, recognized as one of the most rigorous single payer healthcare systems in the world. · The Interventional Procedures Advisory Committee (IPAC) has now started its review of the safety and efficacy of RefluxStop™. IPAC is part of the U.K.’s National Institute for Health and Care Excellence (NICE), which advises

Sedana Medical secures data exclusivity and market protection for Sedaconda[®] (isoflurane) until 2031

Sedana Medical AB (publ) announces that the European Medicines Agency’s Paediatric Committee has issued a positive opinion regarding the compliance with the company’s Paediatric Investigation Plan. This confirms data exclusivity and market protection for Sedana Medical’s Sedaconda[®] (isoflurane) until 2031.In 2021, Sedana Medical’s proprietary pharmaceutical Sedaconda (isoflurane) received its first market authorization in Europe for administration via the medical device Sedaconda ACD for inhaled sedation of mechanically ventilated patients in intensive care. As part of the approval,

Findity Revolutionizes Expense Management with the Launch of Expense API

Findity, the leading provider of expense management technology, is proud to announce the launch of its revolutionary solution, the Expense API. This groundbreaking technology empowers businesses to leverage Findity's platform and seamlessly integrate tailored expense management functionality into their existing software suites.Findity’s Expense API allows companies to directly embed expense management capabilities into their apps and web clients, avoiding the significant time and costs required to develop such functionality from scratch. The Expense API provides direct access to Findity’

Eevia Health Plc Interim Report Q3 - 2023

Significant events during the third quarter of 2023:Net sales1 decreased by 20% from KEUR 1 148 in Q3-22 to KEUR 917 in Q3-23. Compared to the second quarter this year, Net sales decreased by 54%, from KEUR 1 985. The gross profit in Q3-23 landed at KEUR 347, a decrease of 52% from KEUR 725 in Q3-22 and down 70% from KEUR 1 352 in Q2-23. The gross margin2 was 38% in Q3-23, down from 63% in Q3-22 and 68% in Q2-23. The decrease since the previous quarters is due to a changing product mix. There was no effect on gross margin from side-stream products in Q3-23. EBITDA in Q3-23 was KEUR 2

Panoro Energy – Invitation to Third Quarter 2023 Results Presentation

Oslo, 22 November 2023 - The third quarter 2023 trading and financial update to be announced on Wednesday 29 November will be available on our website http://www.panoroenergy.com at 07:30 a.m. CET. The company will hold a live webinar presentation at 09:00 a.m. CET on Wednesday 29 November 2023, during which management will discuss the results and operations, followed by a Q&A session. The webinar presentation can be accessed through registering at the link below and the online event will be equipped with features to ask live questions. Joining instructions for participating online or

Desert Control releases its Q3 2023 Report and Year-to-Date Company Update

Desert Control concluded the third quarter with a strengthened financial position and continued consistent execution. The successful Q3 capital raise and the preceding strategic review secured more than NOK 100M in additional liquidity to support the company’s commercialization phase through the first half of 2025. Sandnes, Norway, 22 November 2023 – Desert Control AS (DSRT) announces its third quarter report for the fiscal period ending 30 September 2023. Q3 2023 Highlights · Completed a capital raise of NOK 67.50 million, solidifying the company’s financial runway through H1-

Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation

Company Announcement Nanoform Finland Plc November 22, 2023 08:10 a.m. Finnish time / 07:10 a.m. Swedish time Nanoform Q3 2023: Nanoformed blockbuster drug enters clinic and another nanoformed drug received FDA orphan designation Project Blockbuster is progressing well. The clinical manufacture of nanoformed material for the project has been done and our partner has successfully made tablets. The clinical trials are expected to start before year end and the results are expected in 1Q24. If the results are positive, the targeted timeline for one or several license/commercial

Gjensidige Forsikring Capital Markets Day 2023: Releasing the full potential

Gjensidige Forsikring hosts its Capital Markets Day today at 09:00 CET. Presentations will be held by Geir Holmgren, Chief Executive Officer of Gjensidige, and key members of the Group executive management team. The presentations will provide a review of the Group's strategy and goals, as well as operational priorities and the Group's strong capabilities.  - I am proud to present new and more ambitious financial targets, and to confirm sustainability targets in line with the Paris agreement. I am certain that our strong capabilities will enable us to release the full potential in

Heatcube successfully passed Power Market Test to provide flexibility services to the Danish electricity market

Oslo, Norway, 22 November 2023 - Kyoto Group is thrilled to announce that the Heatcube at Norbis Park (Nordjylland Power Station) in Aalborg, Denmark, has passed the Power Market Test required to provide flexibility services to the electricity market in the DK1 grid area.By proving a fast and reliable charging response, Kyoto’s Heatcube at Norbis Park successfully passed the Power Market Test required to qualify for participation in the balancing market in DK1. This will enable Nordjylland Power Station to utilize the aFRR and mFRR market to minimize the price of electricity, which

Everfuel – Q3 2023: Executing strategy realignment and progressing HySynergy 1 towards start-up

Herning, 22 November 2023 – Everfuel A/S today published its third quarter 2023 financial results. Key events · Everfuel and Hy24 signs JV agreement for green hydrogen infrastructure in the Nordics · JV completes HySynergy 1 acquisition as first investment under the EUR 200 million framework · Implementing realigned strategy focused on scaling green hydrogen production and Alternative Fuels Infrastructure Regulation (AFIR) ready heavy duty hydrogen mobility solutions · HySynergy 1 progressing according to updated timeline with expected start up in Q1 2024 supported by fully

SAS receives court approval to enter into investment agreement in its exit financing solicitation process

SAS announces that the U.S. Bankruptcy Court for the Southern District of New York (the “Court”) has approved SAS’ entry into the investment agreement with the winning bidder consortium in SAS’ exit financing solicitation process. The winning bidder consortium consists of Castlelake, L.P., on behalf of certain funds or affiliates (“Castlelake”), Air France-KLM S.A. and Lind Invest ApS, together with the Danish state (collectively, the “Investors”).On November 4, 2023, SAS announced that it had entered into an investment agreement with the Investors, subject to approval by the Court. The

Nordea Bank Abp: Repurchase of own shares on 21.11.2023 and technical correction to an earlier release

Nordea Bank AbpStock exchange release – Changes in company’s own shares21.11.2023 at 22.50 EET Nordea Bank Abp (LEI: 529900ODI3047E2LIV03) has on 21.11.2023 completed repurchases of own shares (ISIN: FI4000297767) as follows: +----------+-------+-------------------+-------------------+| Trading |Number | Weighted average |Total cost, EUR* **||venue (MIC| of |price / share, EUR*| || Code) |shares | ** | |+----------+-------+-------------------+-------------------+|XHEL |72,491 |10.34 |749,506.20

Elos Medtech applies for de-listing from Nasdaq Stockholm

The board of directors of Elos Medtech has today resolved to apply for de-listing of the Company’s shares from Nasdaq Stockholm as a result of TA Associates, through EM Intressenter AB (“EM Intressenter”), controlling more than 90 percent of the shares in Elos Medtech AB (publ) (“Elos Medtech” or the “Company”), today having initiated compulsory redemption of the remaining shares in the Company. EM Intressenter has informed the board of directors of Elos Medtech that EM Intressenter initiates compulsory redemption of the remaining shares in Elos Medtech and requested that the shares in

InDex Pharmaceuticals discontinues cobitolimod phase III program

· Independent Data Monitoring Committee (DMC) advises that cobitolimod is unlikely to meet the primary endpoint upon completion of Induction Study 1 · More information regarding next steps will be provided once a thorough analysis of the data from Induction Study 1 has been completed 21 November, 2023 – InDex Pharmaceuticals Holding AB (publ) (“InDex Pharmaceuticals”) today announces that an independent DMC has completed the planned dose selection analysis including safety review and assessment for futility in Induction Study 1 of the phase III program CONCLUDE. The DMC advises that

EM Intressenter AB initiates compulsory redemption proceedings

EM Intressenter AB (“EM Intressenter”), holding approximately 94.3 percent of the shares and approximately 83.6 percent of the votes in Elos Medtech (“Elos Medtech” or the “Company”), has today initiated compulsory redemption of the remaining shares in Elos Medtech. Elos Medtech will notify the minority shareholders that compulsory redemption has been requested and that the minority shareholders will have the opportunity to, no later than two weeks from the date of the notification, in writing report that they wish to bring their own action and state a joint arbitrator. If shareholders to

There are no items matching the current filter
There are no more items matching the current filter
Back to top